SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

“TAVR with the Sapien 3 platform demonstrated comparable 7-year durability to surgery, supporting its use as a treatment option in lifetime management of low-risk patients with symptomatic severe AS,” ...

Last month, Edwards Lifesciences recalled its SAPIEN 3 Ultra Delivery System after reports of burst balloons during implantation, resulting in significant difficulty retrieving the valve into the ...

The U.S. FDA noted in a series of Federal Register declarations that several device makers are working with the Patent and Trademark Office to claim regulatory review times for their devices, ...

EW's TMTT sales may rise 57.1% in Q2, driven by global demand for PASCAL and EVOQUE systems. EW's TAVR revenue likely rose 5.2%, backed by U.S. and EU adoption of SAPIEN 3 Ultra RESILIA. EW's Surgical ...